Literature DB >> 21655917

Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.

Lih-Ching Hsu1, David E Durrant, Ching-Chun Huang, Nai-Wen Chi, Riccardo Baruchello, Riccardo Rondanin, Cinzia Rullo, Paolo Marchetti, Giuseppina Grisolia, Daniele Simoni, Ray M Lee.   

Abstract

Hemiasterlins are cytotoxic tripeptides with antimicrotubule activity originally isolated from marine sponges. We have developed new hemiasterlin derivatives BF65 and BF78 that are highly potent to induce cancer cell death in the low nanomolar range. Examination of their mechanisms of cell cycle arrest and disruption of microtubules revealed an unusual characteristic in addition to anti-tubulin effect. Immunofluorescence staining revealed that A549 lung carcinoma cells treated with BF65 or BF78 exhibited both monopolar and multipolar mitotic spindles. Centrosomes were separated with short spindle microtubules in cells with multipolar spindles. In vitro tubulin polymerization assay confirmed that both BF65 and BF78 were highly potent to inhibit tubulin polymerization. These two compounds induced the formation of monoastral spindles suggesting that they might be inhibitors of mitotic kinesins such as KSP/Eg5. However, kinetic measurement of microtubule activated kinesin ATPase activity demonstrated that unlike the positive control monastrol, neither BF65 nor BF78 suppressed KSP/Eg5 activity. Hence the effect may be a variant form of tubulin inhibition. Similar to vinca alkaloids, BF compounds synergized with a colchicine site microtubule inhibitor stilbene 5c both in vitro and in vivo, which may provide a potential drug combination in the future clinical application.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21655917     DOI: 10.1007/s10637-011-9702-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  37 in total

1.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.

Authors:  Raimond B G Ravelli; Benoît Gigant; Patrick A Curmi; Isabelle Jourdain; Sylvie Lachkar; André Sobel; Marcel Knossow
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

2.  Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin.

Authors:  Galina Kuznetsov; Karen TenDyke; Murray J Towle; Hongsheng Cheng; Junke Liu; Joanne P Marsh; Shawn E R Schiller; Mark R Spyvee; Hu Yang; Boris M Seletsky; Christina J Shaffer; Veronique Marceau; Ye Yao; Edward M Suh; Silvio Campagna; Francis G Fang; James J Kowalczyk; Bruce A Littlefield
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

3.  Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein.

Authors:  A Lopez-Girona; B Furnari; O Mondesert; P Russell
Journal:  Nature       Date:  1999-01-14       Impact factor: 49.962

Review 4.  Novel agents that target tublin and related elements.

Authors:  Eric K Rowinsky; Emiliano Calvo
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

5.  Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Authors:  Sanaa M Nabha; Ramzi M Mohammad; Mahmoud H Dandashi; Brigitte Coupaye-Gerard; Amro Aboukameel; George R Pettit; Ayad M Al-Katib
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

6.  Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.

Authors:  Matthew M Cooney; Tomas Radivoyevitch; Afshin Dowlati; Beth Overmoyer; Nathan Levitan; Kelly Robertson; Sandra L Levine; Kathleen DeCaro; Carol Buchter; Anne Taylor; Bruce S Stambler; Scot C Remick
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

7.  A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

Authors:  Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour
Journal:  Invest New Drugs       Date:  2007-10-26       Impact factor: 3.850

8.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

9.  Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Authors:  David C Blakey; F Russell Westwood; Mike Walker; Gareth D Hughes; Peter D Davis; Sue E Ashton; Anderson J Ryan
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

10.  Eg5 steps it up!

Authors:  Megan T Valentine; Polly M Fordyce; Steven M Block
Journal:  Cell Div       Date:  2006-12-15       Impact factor: 5.130

View more
  4 in total

1.  Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation.

Authors:  Giordano Lesma; Alessandro Sacchetti; Rouli Bai; Giuseppe Basso; Roberta Bortolozzi; Ernest Hamel; Alessandra Silvani; Nadia Vaiana; Giampietro Viola
Journal:  Mol Divers       Date:  2014-02-06       Impact factor: 2.943

2.  Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.

Authors:  Bruna C Guido; Luciana M Ramos; Diego O Nolasco; Catharine C Nobrega; Bárbara Y G Andrade; Aline Pic-Taylor; Brenno A D Neto; José R Corrêa
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

Review 3.  Recent Advances in Small Peptides of Marine Origin in Cancer Therapy.

Authors:  Qi-Ting Zhang; Ze-Dong Liu; Ze Wang; Tao Wang; Nan Wang; Ning Wang; Bin Zhang; Yu-Fen Zhao
Journal:  Mar Drugs       Date:  2021-02-19       Impact factor: 5.118

Review 4.  A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011.

Authors:  Wamtinga Richard Sawadogo; Marc Schumacher; Marie-Hélène Teiten; Claudia Cerella; Mario Dicato; Marc Diederich
Journal:  Molecules       Date:  2013-03-25       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.